Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Derivative, Gain (Loss) on Derivative, Net

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Derivative, Gain (Loss) on Derivative, Net

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Derivative, Gain (Loss) on Derivative, Net of -$863.55 thousand for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Other Income

us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2026-08-14

  • 2025-06-30: Derivative, Gain (Loss) on Derivative, Net 6 month -$863.55K.
Period endDerivative, Gain (Loss) on Derivative, Net 6 month
2025-06-30-$863.55K
10-Q · filed 2026-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05